MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions...
March 13 2018 - 8:00AM
MannKind Corporation (Nasdaq:MNKD) focused on the
development and commercialization of inhaled therapeutic products
for patients with diseases such as diabetes and pulmonary arterial
hypertension, today announced that research results from two
analyses have been accepted for presentation at the American
Diabetes Association’s 78th Scientific Sessions, June 22-26, 2018
in Orlando, Florida:
- “Improved Postprandial Blood Glucose (PPBG) Excursions with
Technosphere Inhaled Insulin Compared with Aspart in T1D Patients –
STAT Study” will be an oral presentation
- “Improved Time-in-Range (TIR) on Continuous Glucose Monitor
(CGM) with Technosphere Inhaled Insulin (TI) Compared with Aspart
in T1D Patients – STAT Study” will be presented during the
scientific poster session
The STAT study (STudy comparing insulin Aspart
versus Technosphere insulin in patients with type 1 diabetes on
multiple daily injections) is the first MannKind study to include
and prospectively evaluate the use of continuous glucose monitoring
with Afrezza therapy. The dual primary endpoints were
assessment of glucose time-in-range as well as post-prandial
glucose excursions in the 1-4 hour post-meal period.
“We are very pleased with the opportunity to
present the STAT Study results at the 78th Scientific Sessions of
the American Diabetes Association”, stated Dr. Satish Garg (Barbara
Davis Center for Diabetes, University of Colorado Denver), senior
author and principal investigator of the collaborative multicenter
randomized study.
“MannKind welcomes the opportunity to share the
results of this collaborative clinical trial and looks forward to
pursuing additional analyses to assess the clinical use of Afrezza
therapy for mealtime glucose control,” stated David Kendall, MD,
Chief Medical Officer of MannKind Corporation. “We believe
that the STAT Study results will offer important insights into ways
that individuals with diabetes can potentially improve their
experience and outcomes by using mealtime inhaled insulin ’in the
moment.‘ Our long-term goal is to establish inhaled human insulin
as both a useful option and a potential treatment of choice for
those individuals with diabetes requiring mealtime glucose
control.” About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) inhalation powder, the Company's first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.Forward-Looking
Statements
This press release contains forward-looking
statements that involve risks and uncertainties, including
statements regarding therapeutic benefits of Technosphere Inhaled
Insulin. Words such as "believes", "anticipates", "plans",
"expects", "intend", "will", "goal", "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon the MannKind's
current expectations. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the results of
clinical trials and other risks detailed in MannKind's filings with
the Securities and Exchange Commission, including the Annual Report
on Form 10-K for the year ended December 31, 2017 and subsequent
periodic reports on Form 10-Q and current reports on Form
8-K. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking
statements are qualified in their
entirety by this cautionary
statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
MannKind Contact:Rose AlinayaSVP, Investor
Relations818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024